Biotech Values

[stockdak]

MNTA.
I would expect a bump to the low 20s with ANDA approval. If M118 is partnered as Wheeler hopes it will see 30s.

Case 1: 20%

I put in a small chance for this because I could be wrong about Case #2.

Case 2: 70%

Most likely because TEVA and Amphastar are getting the same guidance and IMO MNTAs tech. is not required to fulfill scientific issues for characterization of Lovenox generics.

Case 3: 10%

I put in a nominal % because the FDA OGD is overwhelmed.

Case 4: 0%

FDA seems to be telegraphing approval for the generics if hoops are jumped in correct fashion.